Press coverage about Regenxbio (NASDAQ:RGNX) has trended somewhat positive on Wednesday, Accern Sentiment Analysis reports. Accern ranks the sentiment of news coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Regenxbio earned a media sentiment score of 0.09 on Accern’s scale. Accern also assigned news coverage about the biotechnology company an impact score of 46.691187801342 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
These are some of the media stories that may have impacted Accern Sentiment Analysis’s analysis:
- Regenxbio (RGNX) PT Lowered to $35.00 at Morgan Stanley (americanbankingnews.com)
- Regenxbio (RGNX) Upgraded at Zacks Investment Research (americanbankingnews.com)
- Regenxbio (RGNX) Cut to “Hold” at Zacks Investment Research (americanbankingnews.com)
- Zacks: Brokerages Expect Regenxbio Inc (RGNX) to Announce -$0.69 EPS (americanbankingnews.com)
- U.S. shares mixed at close of trade; Dow Jones Industrial Average down 0.33% (uk.investing.com)
RGNX has been the subject of a number of recent research reports. BidaskClub cut Regenxbio from a “buy” rating to a “hold” rating in a report on Tuesday. Morgan Stanley decreased their price target on Regenxbio from $36.00 to $35.00 and set an “overweight” rating for the company in a research note on Wednesday. Zacks Investment Research raised Regenxbio from a “hold” rating to a “buy” rating and set a $33.00 price target for the company in a research note on Thursday, March 8th. ValuEngine cut Regenxbio from a “hold” rating to a “sell” rating in a research note on Tuesday, November 14th. Finally, Mizuho assumed coverage on Regenxbio in a report on Monday, February 12th. They issued a “neutral” rating and a $28.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and six have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $40.13.
Regenxbio (NASDAQ:RGNX) last announced its quarterly earnings results on Tuesday, March 6th. The biotechnology company reported ($0.51) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.71) by $0.20. The company had revenue of $2.04 million during the quarter. Regenxbio had a negative return on equity of 36.48% and a negative net margin of 704.02%. equities analysts forecast that Regenxbio will post -2.54 earnings per share for the current fiscal year.
In other Regenxbio news, CFO Vittal Vasista sold 5,000 shares of the company’s stock in a transaction that occurred on Tuesday, December 19th. The stock was sold at an average price of $30.00, for a total transaction of $150,000.00. Following the transaction, the chief financial officer now owns 87,277 shares in the company, valued at approximately $2,618,310. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Curran Simpson sold 30,000 shares of the company’s stock in a transaction that occurred on Friday, December 22nd. The stock was sold at an average price of $33.03, for a total value of $990,900.00. Following the transaction, the senior vice president now owns 69,500 shares in the company, valued at approximately $2,295,585. The disclosure for this sale can be found here. Insiders have sold 70,000 shares of company stock valued at $2,148,100 in the last three months. 17.00% of the stock is owned by corporate insiders.
TRADEMARK VIOLATION NOTICE: This piece of content was posted by BBNS and is the property of of BBNS. If you are viewing this piece of content on another website, it was illegally copied and republished in violation of international copyright legislation. The correct version of this piece of content can be accessed at https://baseballnewssource.com/2018/03/14/somewhat-favorable-press-coverage-somewhat-unlikely-to-impact-regenxbio-rgnx-share-price/1972484.html.
Regenxbio Company Profile
REGENXBIO Inc is a clinical-stage biotechnology company. The Company’s gene therapy product candidates are designed to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. The Company develops products candidates across the therapeutic areas of metabolic, neurodegenerative and retinal diseases.
Receive News & Ratings for Regenxbio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regenxbio and related companies with MarketBeat.com's FREE daily email newsletter.